COMT

Cathecol-O-methyl transferase Val158Met genotype is not a risk factor for conversion disorder

E. Armagan, Almacıoglu, M. L., Yakut, T., Köse, A., Karkucak, M., Köksal, O., and Gorukmez, O., Cathecol-O-methyl transferase Val158Met genotype is not a risk factor for conversion disorder, vol. 12, pp. 852-858, 2013.

Alterations in catechol-O-methyltransferase (COMT) activity are involved in various types of neurological disorders. We examined a possible association between the COMT Val158Met polymorphism and conversion disorder in a study of 48 patients with conversion disorder and 48 control patients. In the conversion disorder group, 31 patients were Val/Met heterozygotes, 15 patients were Val/Val homozygotes and 2 patients were Met/Met homozygotes. In the control group, 32 patients were Val/Met heterozygotes and 16 patients were Val/Val homozygotes.

Contribution of catechol-O-methyltransferase Val158Met polymorphism to endometrial cancer risk in postmenopausal women: a meta-analysis

G. Lin, Zhao, J., Wu, J., R. O, A., Zhang, W. - H., Zhang, Y., and Yu, L., Contribution of catechol-O-methyltransferase Val158Met polymorphism to endometrial cancer risk in postmenopausal women: a meta-analysis, vol. 12, pp. 6442-6453, 2013.

Catechol-O-methyltransferase (COMT) is a critical enzyme to detoxify the carcinogenic catechol estrogen and the Val158Met polymorphism of COMT could influence its enzymatic activity. Recent epidemiological studies have investigated the correlation of COMT Val158Met polymorphism with endometrial cancer risk; however, the results are inconsistent. To better evaluate the role of COMT Val158Met in endometrial carcinogenesis, we performed this meta-analysis, considering menopausal status, study quality, ethnicity, and source of controls.

Subscribe to COMT